THE COMPOUND CALLED 3-4-4- (2-PYRIMIDINYL) -1-PIPERAZINYL-BUTYL-2,4-THIAZOLIDINEDIONE WHICH HAS SELECTIVE ANXIOLYTIC ACTIVITY CONSTITUTES A REPRESENTATIVE EXAMPLE OF THE INVENTION.TEMPLE DAVIS L JRDAVIS L. TEMPLE JR. ET RICHARD E. YEAGER
Example 38 (5R)-5-{3-[4-(6-methoxyindazol-3-yl)-2-propylphenoxy]benzy1}-5-methyl-1,3-oxazolidine-2,4-dione HN - 1 15 N-NH Using the procedure of Example 36, the title compound was prepared from (5R)-5-{3-[4-(2-fluoro-4 methoxybenzoyl)-2-propylphenoxy]benzyl}-5-methyl-1,...
In this review we compare expression studies on monocyte subsets as an example to show the integrated possibilities of molecular databases and bioinformatic analysis tools. Monocytes have been recognized as cells with great plasticity and differentiation potential that play a pivotal role in ...
For example, there are reports of significant reductions in levels of C-reactive protein (P < 0.01); small, dense low-density lipoprotein cholesterol particles (P < 0.05); and circulating free fatty acids (P < 0.003), in addition to improvements in the proinsulin-to-insulin ratio (P < ...
This offers a new therapeutic regimen for the treatment of actions mediated by oxytocin, for example induction of uterine contractions, release of prostagiandin, and weakening of milk. Therefore, conditions such as preterm delivery and delivery before Cesarean delivery can be treated by these ...
leukemia, breast cancer, [summary] The present invention, generally or prostate cancer specific cancer; inflammation, for example, relates to substituted heterocycles of certain formula (I) useful for the treatment of inflammatory bowel disease osteoarthritis, rheumatoid arthritis, or Crohn''s disease....
For example, 9–10 days were required for these cells to fully differentiate when cultured in control differentiation medium (i.e., dexamethasone plus insulin). However, treatment with both pioglitazone and insulin promoted obvious differentiation in most of the cells by 3 days. Treatment with ...
Such therapeutics may be useful, for example, in therapy of Type II diabetes, insulin resistance, obesity, impaired glucose tolerance, metabolic syndrome (syndrome x), cardiovascular diseases, atherosclerosis and dyslipidemia. Furthermore, the invention relates to methods for testing whether an ...
The method includes signal transduction device and transcription activation factor 5 (STAT5) antagonist (such as, PPARy agonists), after patient carries out initial course of treatments treatment using anticancer agent (for example, TKI), to eliminate the residual cancer stem cell for leading to ...
For example, coactivators such as DRIP 205/TRAP 220 and TIF-2 are responsible for edema and weight gain and may be classified as "adverse" coactivators, whereas SRC-1, involved in lipid metabolism, is viewed as a "beneficial" coactivator. Further stimulation of PPAR not only leads to ...